- Home
- CGEN vs FDMT Comparison
CGEN vs FDMT Comparison
Compare CGEN & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- FDMT
- Stock Information
- Founded
- CGEN 1993
- FDMT 2013
- Country
- CGEN Israel
- FDMT United States
- Employees
- CGEN N/A
- FDMT N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- CGEN Health Care
- FDMT Health Care
- Exchange
- CGEN Nasdaq
- FDMT Nasdaq
- Market Cap
- CGEN 167.4M
- FDMT 192.2M
- IPO Year
- CGEN 2000
- FDMT 2020
- Fundamental
- Price
- CGEN $1.45
- FDMT $7.09
- Analyst Decision
- CGEN
- FDMT Buy
- Analyst Count
- CGEN 0
- FDMT 9
- Target Price
- CGEN N/A
- FDMT $30.63
- AVG Volume (30 Days)
- CGEN 206.7K
- FDMT 728.8K
- Earning Date
- CGEN 08-06-2025
- FDMT 08-11-2025
- Dividend Yield
- CGEN N/A
- FDMT N/A
- EPS Growth
- CGEN N/A
- FDMT N/A
- EPS
- CGEN N/A
- FDMT N/A
- Revenue
- CGEN $22,144,000.00
- FDMT $33,000.00
- Revenue This Year
- CGEN N/A
- FDMT $9,921.62
- Revenue Next Year
- CGEN $159.40
- FDMT N/A
- P/E Ratio
- CGEN N/A
- FDMT N/A
- Revenue Growth
- CGEN N/A
- FDMT N/A
- 52 Week Low
- CGEN $1.13
- FDMT $2.24
- 52 Week High
- CGEN $2.66
- FDMT $17.41
- Technical
- Relative Strength Index (RSI)
- CGEN 48.38
- FDMT 62.39
- Support Level
- CGEN $1.39
- FDMT $6.09
- Resistance Level
- CGEN $1.46
- FDMT $7.33
- Average True Range (ATR)
- CGEN 0.06
- FDMT 0.50
- MACD
- CGEN 0.00
- FDMT -0.03
- Stochastic Oscillator
- CGEN 52.63
- FDMT 80.42
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.